uniQure N.V. 8K

uniQure N.V. reported Q2 2026 results, outlined regulatory and clinical progress for AMT-130, AMT-260 and AMT-191, and significantly bolstered its cash runway into 2030 with a $259 million follow-on equity offering despite a wider quarterly net loss.

On July 29, 2026, uniQure N.V. reported its second quarter 2026 financial results, highlighted by continued regulatory and clinical progress for its lead gene therapy candidate AMT-130 for Huntington’s disease, including FDA alignment on pursuing an accelerated-approval Biologics License Application in the third quarter of 2026 and parallel U.K. regulatory activity, along with early positive safety and activity signals from AMT-260 in mesial temporal lobe epilepsy and continued development of AMT-191 for Fabry disease. The company also disclosed that dosing in certain AMT-191 cohorts remains paused pending further evaluation of previously reported dose-limiting liver enzyme elevations, but noted these had resolved with protocol-directed immunosuppression, and it updated investors on various upcoming data milestones for its clinical programs. Financially, uniQure strengthened its balance sheet by completing a $259 million follow-on equity offering, increasing its cash, cash equivalents and current investment securities to $810.3 million as of June 30, 2026, which management projects will fund operations into 2030, despite reporting a larger quarterly net loss of $81.1 million driven primarily by higher non-operating expenses including foreign exchange impacts and warrant-liability remeasurement.

Filing Facts

CIK

1590560

Ticker

QURE

Form

8K

Source Type

fda

Accession

0001104659-26-087808

Alert Tier

6